Company News

Published On 25 September

The 4th International Conference on Toxicity Testing Alternatives and Translational Toxicology & The 2nd Asian Congress on Alternatives @ Guangzhou

Date: October 11th, 2018; Thursday, Venue: Guangzhou Baiyun International Conference Center Prof Hanry Yu, co-founder of Invitrocue, will be giving a plenary presentation on: “Heterogeneity and solutions in cell-based models for in vitro toxicity testing applications”. Alternatives and translational toxicology have grown critically in modern toxicology and risk assessment. Meanwhile, alternatives are increasingly demanding for […]

Learn more
Published On 13 September

Oncology: The future of cancer treatment

Our international speakers will present the most important innovations and findings in the field of oncology. Happening on Monday, 1st October 2018, 9am – 3.45pm Venue: Klinikum rechts der Isar der Technischen Universität München Click to Download    

Learn more
Published On 04 September

Business updates

Business updates

Learn more
Published On 13 April

IVQ launches Personalised Cancer Screening Service Onco-PDO

Invitrocue launches world’s first commercial Personalised Cancer Screening Service: Onco-PDO™

Learn more
Published On 13 April

Invitrocue unveils novel cancer detection method, screens first customer in Singapore

Bio-analytic healthcare provider Invitrocue (ASX: IVQ), has advanced its proprietary cancer-detection test by screening its first commercial Onco-PDO customer in Singapore.

Learn more
Published On 28 February

Half Yearly Report and Accounts

Half Yearly Report and Accounts

Learn more
Published On 26 February

Grant from Northern Ireland to commercialize Onco-PDO

Invitrocue secures grant from Northern Ireland to commercialise Onco-PDO

Learn more
Published On 23 February

Investor Presentation

Investor presentation

Learn more
Published On 20 February

Change of Director’s Interest Notice – Jamie Khoo

Change of Director’s Interest Notice – Jamie Khoo

Learn more
Published On 20 February

Change of Director’s Interest Notice – Steven Fang

Change of Director’s Interest Notice – Steven Fang

Learn more
Published On 20 February

Change of Director’s Interest Notice – Hanry Yu

Change of Director’s Interest Notice – Hanry Yu

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 14 February

Change of Director’s Interest Notice

Change of Director’s Interest Notice

Learn more
Published On 18 January

IVQ successfully grows liver cancer organoids

Invitrocue further validates its Onco-PDO technology platform through the successful growth of 14 liver cancer organoids

Learn more
Published On 29 August

IVQ receives award from Singapore government IP office

IVQ receives award from Singapore government IP office

Learn more
Published On 24 July

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

L-R: Dr Benjamin Seet, Executive Director of the Biomedical Research Council, A*STAR; His Excellency Bruce Gosper, the Australian High Commissioner to Singapore; Dr Steven Fang, Chief Executive Officer / Founder, Invitrocue Ltd; The Hon Martin Hamilton Smith, Minister for Trade and Investment, South Australian Government; Dr Raj Thampuran, Managing Director, A*STAR; Professor Ng Huck Hui, […]

Learn more
Published On 03 July

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

July 03, 2017 – Invitrocue Limited (ASX:IVQ), a leading healthcare bio-analytic solutions providers, is pleased to announce that it has been granted Human Research Ethics Committee approval to understand a cancer research study with Sydney’s Garvan Institute of Medical Research, to provide further clinical validation of Invitrocue technology for use in personalised real-time screening of […]

Learn more
Published On 22 May

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

22 May, 2017 – Invitrocue (ASX:IVQ) announced today that it will be expanding its cell-based assaying business into skin and wound healing. Invitrocue will develop robust and easy-to-use in vitro assays to assess the safety and effectiveness of consumer antiseptics and over-the-counter (OTC) wound dressing products. Invitrocue has signed a Master Services Agreement with Mundipharma […]

Learn more
Published On 05 May

A*STAR TV Business Insider – The Story of Invitrocue

Invitrocue is featured in the first episode of A*STAR TV Business Insider. Watch this broadcast as it tells the story of company, the technology and the people.  

Learn more
Published On 22 March

Asia Malaria Images Exhibition

Event: Asia Malaria Images Exhibition Opening Talk (Singapore) Venue: The Pod, Level 16, National Library Board, 100 Victoria Street, Singapore 18806 Date: 09 September 2017, Saturday   Invitrocue is proud to be an official sponsor of the Asia Malaria Image campaign as part of the Company’s corporate social responsibility initiative. Mark this day and visit […]

Learn more
Published On 14 March

Singapore-Australia Cooperation on Science and Technology Takes Off

Singapore-Australia cooperation on science and technology takes off ; Landing Pad start-up accelerator is latest initiative in strategic partnership   The Singapore Government has also boosted co-investment support for promising start-ups specialising in deep-technology, such as medical technology, clean technology and advanced manufacturing and engineering. “Collectively, we expect these initiatives to further boost the local […]

Learn more
Published On 13 March

Second Mention in Speech by Minister Iswaran at the Official Opening of the Australian Landing Pad in Singapore

SPEECH BY MR S ISWARAN, MINISTER FOR TRADE AND INDUSTRY (INDUSTRY), AT THE OFFICIAL OPENING OF THE AUSTRALIAN LANDING PAD IN SINGAPORE, ON MONDAY, 13 MARCH 2017, 1040 HRS, AT BASH (79 AYER RAJAH CRESCENT) International connections are critical to facilitating innovation and supporting Singapore’s startup ecosystem. Excerpt:- 8. One example is home-grown local startup […]

Learn more
Published On 04 March

First Mention in Committee of Supply Debate by Ministry of Trade and Industry

SPEECH BY MR LIM HNG KIANG, MINISTER FOR TRADE AND INDUSTRY (TRADE), DURING THE COMMITTEE OF SUPPLY DEBATE UNDER HEAD V (MINISTRY OF TRADE AND INDUSTRY) ON FRIDAY, 3 MARCH 2017 STAYING OPEN AND CONNECTED Excerpt:- 32.         In addition, Singapore companies can partner larger companies to venture abroad. Invitrocue, a home grown biotechnology firm that was spun-off from A*STAR, […]

Learn more
Published On 23 February

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

February 23, 2017 – Invitrocue (ASX: IVQ) is pleased to announce that the company has signed a Collaborative Research Master Agreement with the Garvan Institute of Medical Research. The aim of the collaboration is to provide further medical validation of Invitrocue’s technology for use in personalised real time screening of cancer drugs. It is envisaged […]

Learn more
Published On 10 November

PharmaBoardroom Interview

Biotech CRO InvitroCue Executive director Dr. Steven Fang explains how their technology has disrupted the current clinical trials landscape and the importance of leveraging innovative technologies in meeting future healthcare needs. Interviewer: Could you please introduce to our international readers the main activities of InvitroCue as well as the milestones since its foundation in 2012? […]

Learn more
Published On 28 October

Annual General Meeting 2016

Invitrocue (ASX:IVQ) will be holding our inaugural AGM on the 30th of  November. Click here for AGM Notice.

Learn more
Published On 24 October

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

October 24, 2016 – Invitrocue (ASX:IVQ) announced a collaboration agreement with the  Cancer Therapeutics and Stratified Oncology Group at the Genome Institute of Singapore (GIS), A*STAR. Invitrocue and GIS will jointly conduct a pilot feasibility study using Invitrocue’s cell-based 3D scaffolding technology (Onco-PDO™) to culture colorectal cancer organoids. The aim of the study is to […]

Learn more
Published On 06 September

InvitroCue Awarded A*STAR Tender

September 05, 2016 – InvitroCue (ASX:IVQ) has been awarded a tender by the Institute of Bioengineering and Nanotechnology, Agency for Science, Technology and Research (A*STAR), to supply and deliver Hepatocue 96-well plates and 3D-Cellusponge 96-well plates. A*STAR will be utilizing InvitroCue’s technologies to advance research on non-animal approaches to chemical safety testing under an international […]

Learn more
Published On 22 August

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

August 22, 2016 – InvitroCue Limited (ASX:IVQ) has announced that its wholly owned subsidiary InvitroCue Biomedical Service Suzhou (“InvitroCue Suzhou”) has signed a Strategic Partnership Agreement with QIAGEN Suzhou Translational Medicine Co. Limited (“QIAGEN Suzhou”).   Pursuant to the agreement, InvitroCue Suzhou and QIAGEN Suzhou will jointly accelerate the discovery of biomarkers and translational medicine […]

Learn more
Published On 28 July

InvitroCue Announces New Program Focused on Hepatitis B Virus

July 28, 2016 – InvitroCue (ASX:IVQ), has signed a research collaboration program with Yong Loo Lin School of Medicine, National University of Singapore. The program will focus on InvitroCue’s “3D human liver” to model an in vitro system for the study of chronic Hepatitis B infection. If the program delivers promising data and results by […]

Learn more
Published On 11 July

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. […]

Learn more
Published On 14 June

Investor Presentation (Mandarin)

Download the Investor Presentation translated in Simplified Mandarin. Refer to the announced English version herein.  

Learn more
Published On 24 May

InvitroCue Announces Publication of Results in Human Stem Cell Derived Hepatocytes in 3D Culture System Used in Liver Drug Testing Assays

May 24, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced that the results of the Company’s 3D Culture System for growing stem cell derived hepatocytes have been published in the May print and web editions of Molecular Pharmaceutics (Mol. Pharmaceutics). Mol. Pharmaceutics is an official peer-reviewed online scientific journal which focuses […]

Learn more
Published On 20 May

InvitroCue Convenes Scientific and Medical Advisory Board

May 20, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has today announced the appointment of leading experts to its newly formed Scientific and Medical Advisory Board (“SAB”). The SAB will guide the company in a broad range of activities including in vitro cell-based assays, patient-derived organoids, digital pathology and medical imaging. “We are […]

Learn more
Published On 16 May

InvitroCue Announces Malaria Initiative

May 16, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today a key initiative on Malaria to identify and evaluate new drug targets to tropical infectious diseases. Following its successful initiative on leishmaniasis, InvitroCue establishes an open and collaborative strategy that involves integrated partnerships and networks between academic infectious diseases institutes and pharmaceutical […]

Learn more
Published On 12 May

InvitroCue Expands 3D Cell-based Platform for Oncology

May 12, 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, announces today that it is planning to enter the oncology testing market for drugs to provide data points in selected solid tumours. Using its revolutionary 3D cell-based technology and proprietary processes, InvitroCue will be able to culture patient derived cancer cells in its laboratories […]

Learn more
Published On 25 April

Professor Hanry Yu Presented with A*STAR Scientist-Entrepreneur Award

A*STAR Awards 2016 – Award Ceremony Professor Hanry Yu’s Acceptance Speech “It is with great pleasure that I receive the A*STAR Scientist-Entrepreneur Award. Special thanks to A*STAR for selecting me and an enormous salute to all of this year’s nominees each of whom have made incredible contributions to the scientific and biomedical ecosystem in Singapore. This […]

Learn more
Published On 08 April

InvitroCue and SciKon Innovation Forge an Alliance to Create the Future of Perfused Human Liver Tissue

SINGAPORE and RESEARCH TRIANGLE PARK, NORTH CAROLINA USA April 08, 2016 – InvitroCue (ASX:IVQ), the in-vitro cell-based assaying company, and SciKon Innovation Inc. a US-based life sciences company,  today announce a strategic technology partnership that will enable InvitroCue to enhance its focus on delivering customer-centric innovation for its high-value biopharmaceutical customers. The agreement will allow […]

Learn more
Published On 08 April

InvitroCue Launches Cellacyl: Proprietary Acyl Glucuronide Detection Assay

SINGAPORE April 08, 2016 – InvitroCue (ASX:IVQ), the in vitro cell-based assaying company, today announce the global launch of its proprietary CellacylTM assay to monitor and screen carboxylated drug compounds for acyl glucuronides in liver-derived cells (hepatocytes), enabling pharmaceutical companies to streamline compound-ranking during the early phases of drug discovery. Cellacyl is a unique in […]

Learn more
Published On 14 March

InvitroCue – A Singapore-based Startup That Is Transforming Bioanalytics

InvitroCue, a Singapore-based biotech company, made its debut on the Australian Securities Exchange (ASX: IVQ) on Jan 27 2016, – just four years after its founding. The company, a spin-off from A*STAR, announced that it had raised an AUD 3.15 Million (SGD3.17 Million) on the ASX through a reverse takeover. On March 1st, 2016, they […]

Learn more
Published On 09 March

Agreement with London School of Hygiene & Tropical Medicine

Download the InvitroCue Agreement PDF here: Agreement

Learn more
Published On 09 March

Novel 3D in vitro Techniques for Modeling leishmaniasis

09 March 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with London School of Hygiene & Tropical Medicine (London), recently signed an Agreement under which they started a collaboration using 3D in vitro technologies to establish leishmania spp. infection in vitro models. These technologies, when integrated, could offer a novel model for the in vitro […]

Learn more
Published On 05 March

Bioanalytics Start-up InvitroCue is Preparing for the Global Stage

Featured on The Edge Enterprise, The Week of 07 March 2016 Biotech entrepreneur Dr Steven Fang is no stranger to the start-up scene … Fang recently listed bio-analytics firm InvitroCue on the ASX, just four years after the company was founded. “What we’re doing today breaks almost all records. We took four years to build […]

Learn more
Published On 05 March

InvitroCue Expands Cell-based Lab in Suzhou to Meet Client’s Increase China Focus

SINGAPORE and CHINA – March 05, 2016 – InvitroCue Pte Ltd and InvitroCue Biomedical Service Suzhou, a wholly owned subsidiary, today jointly announced the expansion of a cell-based laboratory facility in Suzhou to enhance the company’s current service offerings, and to meet current and future growth of the drug development in China. The expansion is […]

Learn more
Published On 24 February

Insight to InvitroCue’s Success – from Invention to IPO

Insight to InvitroCue’s Success – from Invention to IPO February 23, 2016   On Jan 27 2016, local biotech company InvitroCue made its debut on the Australian Securities Exchange (ASX: IVQ) – just four years after its founding. The company, a spin-off from A*STAR, just announced that it had raised an AUD 3.15 Million (SGD3.17 […]

Learn more
Published On 15 February

InvitroCue Participates in Society of Toxicology Annual Meeting and ToxExpo

Society of Toxicology 55th Annual Meeting and ToxExpo™ March 13-17, 2016 | New Orleans Ernest N. Morial Convention Center , LA Booth #1653| contact@invitrocue.com 15 February 2016, Singapore: Invitrocue Limited (ASX:IVQ) is honoured to participate in this year’s 55th Annual Meeting. 2016 promises to be an exciting year for InvitroCue. In only our second year of participation, […]

Learn more
Published On 15 February

New Consortium on NASH Pilots Organ Function-on-a-Chip

15 February 2016 – InvitroCue Pte Ltd (“IVQ” Singapore), together with TNO (the Netherlands), and Takara Bio Europe AB (Sweden), recently signed an Agreement under which they started a collaboration using different technologies to develop a model of non-alcoholic steatohepatitis (NASH). This collaborative project is part of TNO’s Early Research Program ‘Organ on-a-chip’, for which they […]

Learn more
Published On 05 February

Artificial Human Liver Developed for Drug Testing

Featured on Singapore News & Top Stories – The Straits Times 05 Feb 2016 By Lin Yangchen The liver is an important organ in drug testing because all drugs pass through it to be detoxified, a process that reduces or removes harmful substances from the body. By constructing a microscopic 3D scaffold to cultivate liver cells […]

Learn more
Published On 04 February

InvitroCue Holds Targeted Investor Road Show on 15 February

04 February 2016, Singapore and Sydney: Invitrocue Limited (ASX:IVQ) is pleased to announce Dr Steven Fang, the company’s Executive Director, shall hold an Investor Road Show beginning on 15 February. Selected journalists, analysts, institutional investors can get to know the company’s global expansion plan and attractive investment opportunity. Dr Fang will provide an update about InvitroCue’s […]

Learn more
Published On 01 February

ImageIQ And InvitroCue Forge Partnership To Advance Quantitative Image Analysis For Preclinical Researchers In Asia

CLEVELAND, OHIO and SINGAPORE – February 01, 2016 – ImageIQ, an innovative Imaging Software and Contract Research Organization supporting preclinical research and clinical trials, announced today an agreement with InvitroCue (“IVQ”), a Singapore-based provider of biomedical quantitative image analytic products and services, to enhance and accelerate preclinical research through the use of cloud-based image analysis […]

Learn more
Published On 30 January

80% Of Liver Cancer Patients Are In Asia

全球肝癌病人 80% 在亚洲地区 (Picture from Left to Right) A/Prof Toh Han Chong Deputy Director NCCS, Prof Pierce Chow Senior Consultant Surgeon NCCS and Dr Steven Fang Executive Director IVQ at the MOU Signing Ceremony held on 29 Jan 2016.   《新明日报》刊。 Source: http://www.nccs.com.sg/Newsroom/MediaReleases/2016MediaReleases/Pages/29Jan2016_1.aspx

Learn more
Published On 28 January

Biotech Firm Shows The Way Onto The Global Stage

28 Jan 2016 The Business Times By Claire Huang SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage. The biotech firm, a spin-off from the Agency for […]

Learn more
Published On 28 January

NCCS And InvitroCue To Develop Quantitative Cancer Imaging And Radiomics Applications For Treatment Of Liver Cancer Patients

National Cancer Centre Singapore (NCCS) has signed a Memorandum of Understanding (MOU) with InvitroCue Pte Ltd (IVQ) to collaborate on research in the development of applications that will improve treatment outcomes in primary liver cancer or Hepatocellular Cacinoma (HCC). This translational and clinical research in Radiomics is an initiative that will move precision medicine into clinical […]

Learn more
Published On 08 April

InvitroCue and Swiss InSphero MOU Signing Ceremony

MOU Signing Ceremony between InvitroCue and Swiss InSphero and Technology Sharing Session On 8th April, 2015, the technology sharing session entitled “Cell Modeling and Analysis Method for Drug Research” was held at NUS (Suzhou) Research Institute. As one of the activities of Singapore-China (Suzhou) Innovation Centre’s NUSRI International Technology Commercialisation platform, the platform steadily supports […]

Learn more